Table 2.
Characteristics of included pediatric randomized controlled trials of fatigue.
| Characteristic | Previous in 2018 CPG n (%) | New in 2023 CPG update n (%) | Total number RCTs n (%) |
|---|---|---|---|
| Number of studies | 6 | 14 | 20 |
| Study population setting | |||
| Cancer | |||
| Leukemia | 2 (33) | 2 (14) | 4 (20) |
| More than one cancer | 2 (33) | 8 (57) | 10 (50) |
| HCT | 1 (17) | 2 (14) | 3 (15) |
| Both cancer and HCT | 1 (17) | 2 (14) | 3 (15) |
| Timing of intervention | |||
| During cancer treatment | 6 (100) | 12 (86) | 18 (90) |
| Following end of cancer treatment | 0 (0) | 2 (14) | 2 (10) |
| Fatigue eligibility criterion for enrollment | 0 (0) | 2 (14) | 2 (10) |
| Intervention group type | |||
| Mind and body | 3 (50) | 1 (7) | 4 (20) |
| Physical activity | 1 (17) | 7 (50) | 8 (40) |
| Other (including combination) | 2 (33) | 6 (43) | 8 (40) |
| Control group type | |||
| Usual care or wait list | 5 (83) | 9 (64) | 14 (70) |
| Placebo or sham | 1 (17) | 0 (0) | 1 (5) |
| Attention control | 0 (0) | 2 (14) | 2 (10) |
| Other | 0 (0) | 3 (21) | 3 (15) |
| Biomarker measurement | 0 (0) | 1 (7) | 1 (5) |
| Risk of bias adequacy | |||
| Sequence generation | 4 (66) | 11 (79) | 15 (75) |
| Allocation concealment | 2 (33) | 7 (50) | 9 (45) |
| Participants, personnel blinded | 1 (17) | 1 (7) | 2 (10) |
| Outcome assessors blinded | 1 (17) | 6 (43) | 7 (35) |
| Lack of attrition bias | 4 (66) | 9 (64) | 13 (65) |
| Free of selective reporting | 6 (100) | 14 (100) | 20 (100) |
Abbreviations: CPG, clinical practice guideline; HCT, hematopoietic cell transplant; RCT, randomized controlled trial.